Please Wait.....
Report
Japan Biosimilars Market Assessment, By Product Class [Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-Inflammatory Agents, Others], By Indication [Oncology, Growth Hormone Deficiency, Blood Disorders, Chronic and Autoimmune Disorders, Infectious Diseases, Others], By Distribution Channel [Hospitals, Cancer Care Centers, Others], By Region, Opportunities and Forecast, FY2019-FY2033F
Market Report I 2025-06-16 I 125 Pages I Market Xcel - Markets and Data
Japan biosimilars market is projected to witness a CAGR of 9.33% during the forecast period FY2026-FY2033, growing from USD 543.52 million in FY2025 to USD 1109.50 million in FY2033. The Japan biosimilars market is being propelled by the growing need for affordable healthcare solutions and government policies promoting biosimilar adoption. The oncology segment is witnessing significant expansion, driven by the increasing burden of cancer and the approval of biosimilar monoclonal antibodies. Strategic partnerships between domestic and global companies are further strengthening market penetration and product availability.
Rising Demand for Cost-Effective Therapies Fueling Biosimilar Adoption in Japan
The biosimilars market in Japan is experiencing significant growth driven by the increasing need for cost-effective treatment alternatives, especially in the fields of oncology and chronic disease management. As the population ages and healthcare expenses rise, biosimilars present a financially viable option compared to biologic therapies, maintaining both efficacy and safety. The Japanese government is actively encouraging the adoption of biosimilars through supportive policies and reimbursement incentives, with the goal of alleviating the national healthcare burden. Hospitals and cancer treatment facilities are progressively integrating biosimilars to enhance patient access to treatment. Additionally, public awareness initiatives that emphasize the equivalence of biosimilars to their reference biologics are facilitating market growth. For example, in December 2023, Biocon Biologics, a subsidiary of Biocon, announced a partnership with Sandoz, granting Sandoz exclusive rights to market, sell, and distribute the Adalimumab biosimilar for subcutaneous administration in Japan.
Increasing Oncology Focus Enhancing the Biosimilars Segment Growth
The increasing incidence of cancer cases in Japan has resulted in a notable surge in the demand for biosimilar monoclonal antibodies. Oncology biosimilars, especially those aimed at breast cancer, lymphoma, and colorectal cancer, are becoming essential for hospitals that are looking for cost-effective treatment options. Regulatory bodies in Japan are expediting the approval processes for oncology biosimilars, thereby enhancing the range of available therapeutic alternatives. Furthermore, collaborations between local pharmaceutical firms and international biosimilar developers are improving access to innovative biosimilar treatments. The heightened emphasis on oncology-specific biosimilars is fostering significant growth in this sector and establishing Japan as a prominent biosimilars market within Asia. For instance, in January 2025, Celltrion announced that its biosimilar therapy for breast and gastric cancer, Herzuma (trastuzumab), has achieved a 74 percent market share in Japan, a key pharmaceutical market in Asia, as of November. After surpassing the original product in market share during the second quarter of 2021, Herzuma has sustained its leading status for three consecutive years and is now increasing its lead over competitors.
Strategic Collaborations Strengthening Japan's Position in the Global Biosimilars Landscape
The strategic partnerships between Japanese pharmaceutical companies and global biosimilar firms are driving market growth. These collaborations are centered on the joint development, production, and marketing of biosimilars that meet the specific regulatory and clinical requirements of Japan. Firms are making significant investments in local manufacturing facilities to adhere to Japan's stringent quality regulations, thereby enhancing the domestic supply chain. Additionally, these partnerships are enabling Japanese companies to launch highly competitive products in both local and international markets. This movement is positioning Japan as a key center for biosimilar innovation and commercialization. For instance, in February 2025, Biocon Biologics revealed its collaboration with Janssen to launch a biosimilar medication targeting autoimmune diseases in Europe, the United Kingdom, Canada, and Japan. As a subsidiary of Biocon Ltd, the company has successfully negotiated a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson, which supports the commercialization of its proposed biosimilar Bmab 1200, intended as an alternative to Stelara.
Future Market Scenario (FY2026 - FY2033F)
The biosimilars market in Japan is set for substantial growth in the upcoming years, fueled by rising healthcare expenses, an increasingly aging demographic, and a heightened demand for affordable biologic therapies. Government initiatives aimed at fostering biosimilar adoption, along with expedited regulatory approvals, will further propel market development. The growing prevalence of oncology, autoimmune diseases, and chronic conditions is generating a significant demand for cost-effective therapeutic options. Moreover, domestic pharmaceutical firms are progressively partnering with global entities to enhance the biosimilars pipeline and launch innovative products. Improvements in manufacturing technologies and quality assurance processes will also boost the competitiveness of biosimilars in Japan. With the expansion of indications and the introduction of new products, Japan is anticipated to become a prominent biosimilars market within the Asia-Pacific region.
Key Players Landscape and Outlook
Key players in the biosimilars industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, Owen Mumford's exclusive partnership with NIPRO CORPORATION, based in Osaka, for the distribution of the UniSafe drug delivery device, has experienced significant early growth in the sales of combination products in Japan. Since its introduction in late 2023, the product has rapidly captured a substantial portion of the market, including the original biologic combination product. This achievement within the initial three months of its commercial release has surpassed the expectations of both NIPRO and Owen Mumford.
1. Project Scope and Definitions
2. Research Methodology
3. Impact of U.S. Tariffs
4. Executive Summary
5. Japan Biosimilars Market Outlook, FY2019-FY2033F
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Product Class
5.2.1.1. Monoclonal Antibodies
5.2.1.1.1. Adalimumab
5.2.1.1.2. Infliximab
5.2.1.1.3. Rituximab
5.2.1.1.4. Trastuzumab
5.2.1.1.5. Others
5.2.1.2. Recombinant Hormones
5.2.1.2.1. Insulin
5.2.1.2.2. Erythropoietin
5.2.1.2.3. Others
5.2.1.3. Immunomodulators
5.2.1.4. Anti-Inflammatory Agents
5.2.1.5. Others
5.2.2. By Indication
5.2.2.1. Oncology
5.2.2.2. Growth Hormone Deficiency
5.2.2.3. Blood Disorders
5.2.2.4. Chronic and Autoimmune Disorders
5.2.2.5. Infectious Diseases
5.2.2.6. Others
5.2.3. By Distribution Channel
5.2.3.1. Hospitals
5.2.3.2. Cancer Care Centers
5.2.3.3. Others
5.2.4. By Region
5.2.4.1. North [Hokkaido and Tohoku]
5.2.4.2. Central [Kanto and Chubu]
5.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
5.3. Market Map Analysis, FY2025
5.3.1. By Product Class
5.3.2. By Indication
5.3.3. By Distribution Channel
5.3.4. By Region
6. Demand Supply Analysis
7. Value Chain Analysis
8. Porter's Five Forces Analysis
9. PESTLE Analysis
10. Pricing Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Regulatory Approvals
13.2. Clinical Trials
14. Patent Landscape
15. Case Studies
16. Competitive Landscape
16.1. Competition Matrix of Top 5 Market Leaders
16.2. SWOT Analysis for Top 5 Players
16.3. Key Players Landscape for Top 10 Market Players
16.3.1. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
16.3.1.1. Company Details
16.3.1.2. Key Management Personnel
16.3.1.3. Products and Services
16.3.1.4. Financials (As Reported)
16.3.1.5. Key Market Focus and Geographical Presence
16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
16.3.2. Daiichi Sankyo Company, Limited
16.3.3. Mochida Pharmaceutical Co., Ltd
16.3.4. Teva Japan Private Limited
16.3.5. Eli Lilly and Company (Japan) Pvt. Ltd.
16.3.6. Pfizer Japan Inc.
16.3.7. Celltrion Healthcare Japan Private Limited
16.3.8. JCR Pharmaceuticals Co Ltd
16.3.9. LG Life Sciences Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
17. Strategic Recommendations
18. About Us and Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security